Pivanex and Docetaxel Combination Therapy for Chemotherapy Resistant Advanced Non-Small Cell Lung Cancer
Data Collection
Bronchial Neoplasms+7
+ Carcinoma, Bronchogenic
+ Carcinoma, Non-Small-Cell Lung
Treatment Study
Summary
Study start date: September 1, 2003
Actual date on which the first participant was enrolled.This study focuses on a specific type of lung cancer known as advanced non-small cell carcinoma of the lung (NSCLC) that resists chemotherapy. The trial aims to understand if combining two drugs, Pivanex and Docetaxel, can offer better results than using Docetaxel alone. Pivanex, a histone deacetylase inhibitor, encourages tumor differentiation and/or apoptosis, and has shown promise in previous trials. Docetaxel is an approved second-line treatment for non-small cell lung cancer. The study hopes to address the challenge of chemotherapy resistance in lung cancer, potentially improving patient care and outcomes. In this open-label, randomized trial, participants with NSCLC who have undergone no more than one prior platinum-containing chemotherapy regimen are divided into two groups. One group receives both Pivanex (intravenously on Days 1-3) and Docetaxel (intravenously on Day 4), while the other group receives only Docetaxel (intravenously on Day 1). Both treatments repeat every 21 days until disease progression or treatment withdrawal. The study evaluates the survival, time to disease progression, tumor responses, and safety profile of patients in both groups to determine the effectiveness and safety of the combined therapy compared to Docetaxel alone.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.225 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 8 locations
Wilshire Oncology Medical Group
La Verne, United StatesOpen Wilshire Oncology Medical Group in Google MapsHematology and Oncology Specialists, LLC
New Orleans, United StatesHemOnCare
Brooklyn, United StatesMontefiore Medical Center, Department of Oncology
The Bronx, United States